Combining expertise to transform and accelerate drug discovery and development
No one business can revolutionise the way medicines are discovered and developed alone. We enable our partners to leverage the benefits and insights of the Benevolent Platform® to drive drug discovery innovation and generate novel treatments. We work across every stage of the drug discovery process from Target Identification, Molecular Design through to Clinical Development and Precision Medicine.
Our successful multi-target collaboration with AstraZeneca, initially focused on chronic kidney disease and idiopathic pulmonary fibrosis, and was expanded to include heart failure and systemic lupus erythematosus in January 2022. AstraZeneca has so far chosen to add five novel targets from the collaboration to its drug portfolio.